mRNA Treatment for Alport Syndrome

Intravenous mRNA therapy significantly reduced proteinuria and blood urea nitrogen in mice with X-linked Alport syndrome.

• Alport syndrome is linked to mutations in type IV collagen genes that impair kidney function.
• Current treatments do not address the genetic cause but aim to delay disease progression.
• Lipid nanoparticles were used to deliver mRNAs for producing collagen IV repair proteins.
• The therapy maintained protective effects against kidney damage as long as it was administered.
• Efficacy diminished when the mRNA therapy was stopped, indicating a need for ongoing treatment.
• The findings suggest potential for mRNA therapies in treating Alport syndrome and similar kidney diseases.

Simplified